Results 151 to 160 of about 223,710 (297)
Molecular Oncology, EarlyView.A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He +8 more
wiley +1 more source
Robustness of radiomics among photon-counting detector CT and dual-energy CT systems: a texture phantom study [PDF]
Lan Zhu +11 more
openalex +1 more source
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Development of a flexible liver phantom for hepatocellular carcinoma treatment planning: a useful tool for training & education [PDF]
Abdulla Al-Thani +8 more
openalex +1 more source
Application of the 4-D XCAT Phantoms in Biomedical Imaging and Beyond
IEEE Transactions on Medical Imaging, 2018 W. Segars +5 more
semanticscholar +1 more source
Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway
Molecular Oncology, EarlyView.Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed +10 more
wiley +1 more source
Trends and Challenges: A 15-Year Review of Imaging and Radiation Oncology Core Anthropomorphic Phantom Audits for Proton Therapy. [PDF]
Int J Part TherDuan L +6 more
europepmc +1 more source
Evaluation of cumulative dose for cone‐beam computed tomography (CBCT) scans within phantoms made from different compositions using Monte Carlo simulations [PDF]
, 2015 Abdullah Abuhaimed +4 more
openalex +1 more source
Molecular Oncology, EarlyView.HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto +13 more
wiley +1 more source